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Emergence of multidrug resistant influenza A(H1N1)pdm09 virus variants in an
immunocompromised child treated with oseltamivir and zanamivir
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Abstract
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Prolonged treatment of an immunocompromised child with oseltamivir and zanamivir for
A(H1N1)pdm09 virus infection led to the emergence of viruses carrying H275Y and/or E119G in the
neuraminidase. When phenotypically evaluated by neuraminidase inhibition, the dual H275Y-E119G
substitution caused highly reduced inhibition by four neuraminidase inhibitors including oseltamivir,
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zanamivir, peramivir and laninamivir.
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INTRODUCTION
Neuraminidase (NA) inhibitors (NAIs) are vital for treating influenza infections among
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immunocompromised patients at high risk for influenza-associated complications and mortality.
Because currently circulating influenza viruses are resistant to M2 blockers, NAIs are the only effective
FDA-approved drugs for treating influenza. The NAIs, orally administered oseltamivir and inhaled
zanamivir, are licensed in most countries, while intravenous peramivir (1) is approved in the USA,

us

Japan, South Korea, China, and inhaled laninamivir (2) in Japan. Intravenous (IV) zanamivir is

undergoing evaluation for treatment of hospitalized patients with severe influenza (3). Use of NAIs in

an

of drug resistance resulting from subtype-specific neuraminidase (NA) mutations (4).

M

The H275Y substitution in the N1 NA is the most commonly observed change associated with
resistance to oseltamivir and peramivir, and can emerge and persist following oseltamivir treatment in
immunocompromised patients infected with influenza A(H1N1)pdm09 (5). Use of zanamivir in patients
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infected with H275Y viruses is associated with reduced viral shedding and provides an alternative
treatment (6). Resistance to zanamivir has rarely been detected in clinical settings, and was first reported
in an influenza B virus with R152K substitution, isolated from an immunocompromised patient (7). The
emergence of I223R has been reported in A(H1N1)pdm09 viruses infecting immunocompromised

ce

patients, often in combination with or after the H275Y substitution has been detected (8) and results in
reduced susceptibility to zanamivir. The variant has emerged after sequential oseltamivir and zanamivir

Ac

treatment. By itself, I223R causes minimal effects on zanamivir susceptibility, but synergizes with
H275Y to produce a greater effect. An I223R-H275Y double mutant exhibited ∼20-fold and ∼10-fold
increases in zanamivir IC50,compared to the wild type virus and the H275Y mutant, respectively (8).
We report the emergence of an influenza A(H1N1)pdm09 virus carrying a newly described
substitution in the NA from an immunocompromised infant following prolonged zanamivir treatment.
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immunocompromised patients who often have sustained viral replication is associated with emergence
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METHODS
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Patient Information
The patient was an 8-month-old infant with familial Hemophagocytic Lymphohistiocytosis

(HLH). The patient had initially developed upper respiratory symptoms and tested positive for influenza
A by PCR (xTAGTM RVP, Luminex Molecular Diagnostics, Inc., Ontario, Canada) at 4 months of age,

us

after being hospitalized for two months to receive immunosuppressive treatment for HLH. The patient
received 5 days of oral oseltamivir and symptoms resolved. Two months later (64 days prior to cord

an

and restarted on oseltamivir after testing positive for influenza A (Table 1). The patient’s respiratory
status worsened and treatment with IV zanamivir was initiated under an emergency investigational new

M

drug request (day –57). Transplantation was delayed due to renal and electrolyte issues. While on
zanamivir, the patient’s respiratory status improved and the patient eventually underwent cord blood
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transplantation for severe HLH that was not responsive to chemotherapy after receiving zanamivir for 57
days. On day 9 following transplantation, he was diagnosed with pulmonary aspergillosis based on
bronchoalveolar lavage, and received antifungal therapy. Zanamivir was discontinued after 73 days of
treatment (17 days following transplantation), when results of the NI assay performed on his clinical

ce

isolate revealed a multi-drug resistant profile. He received intravenous immunoglobulin therapy
throughout the treatment course. He had lymphocyte engraftment on day 27 following transplantation,

Ac

but eventually expired on day 69 due to progressive respiratory failure and pulmonary hemorrhage. No
autopsy was performed.
A nasal wash specimen collected from the infant was submitted to the Centers for Disease

Control and Prevention (CDC) for antiviral susceptibility testing 10 days prior to cord blood
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blood transfusion [day -64]), the patient was re-admitted with diarrhea and mild respiratory symptoms
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transplantation (day -10). Additional clinical specimens were submitted to CDC for evaluation after this
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specimen was fully characterized.

Virus Characterization

The CLIA-certified CDC pyrosequencing assay was used on the day -10 specimen to detect

amino acid substitutions at the NA residues H275, I223, N295 and D199, and was performed on the

us

PyroMark PSQ96™ MA platform (Qiagen, Valencia, CA). A pyrosequencing assay targeting residue
E119 was specifically designed for this study (Supplemental Table S1).

an

Manassas, VA). Plaque purification of viruses was performed in accordance with standard procedures.

M

The fluorescent NI assay was used to determine susceptibilities of virus isolates to oseltamivir
carboxylate (Hoffmann-La Roche, Basel, Switzerland), zanamivir (GlaxoSmithKline, Uxbridge, UK),
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peramivir (BioCryst Pharmaceuticals, Birmingham, AL) and laninamivir (Biota, Melbourne, Australia)
using the NA-Fluor™ Influenza Neuraminidase Assay Kit (Applied Biosystems, Foster City, CA). Drug
concentrations required to inhibit NA activity by 50% (IC50) were determined using JASPR v1.2 curvefitting software (CDC, Atlanta, GA). Fold changes in IC50 were determined by comparing IC50s of test

ce

viruses with a wildtype reference virus, A/California/12/2012 (H1N1)pdm09, and interpreted according
to classification criteria of the World Health Organization Influenza Antiviral Working Group (WHO-

Ac

AVWG).

Sanger sequencing of NA genes was performed using standard procedures, and NA sequence

data was deposited to the Global Initiative on Sharing All Influenza Data (GISAID), under the accession
number EPI531845.

Quantitative PCR analysis of respiratory specimens was performed as previously described (9).
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Virus propagation was performed in Madin-Darby canine kidney (MDCK) cells (ATCC,
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RESULTS
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The respiratory specimen submitted to CDC was obtained 10 days pre-transplantation (-10), after
47 days of zanamivir treatment and was tested with pyrosequencing for markers of NAI resistance

(Table 1). The proportion of H275Y in the virus quasi-species was 23%, which was ~2-fold above the
limit of detection in the pyrosequencing assay (cutoff 10%). The H275Y substitution is a marker of

D199.

an

The virus isolate from this specimen (passage C1) was tested by NI assay (Table 2) and showed
slightly reduced inhibition by oseltamivir (7-fold increase in IC50) and highly reduced inhibition by

M

zanamivir (~1300-fold), peramivir (~170-fold) and laninamivir (~330-fold), compared to the wildtype
reference virus, A/California/12/2012 (H1N1)pdm09. Notably, pyrosequencing of this isolate (C1)
revealed only one NA virus variant, H275Y (5%) and no variants with the other 3 markers. To identify
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molecular changes responsible for the unusual NI assay profile, virus isolate (C1) was subjected to
Sanger sequencing and the E119G substitution was detected.
New primers were designed to extend the pyrosequencing assay to residue E119 (Supplemental
Table S1). Using this assay, the E119G was detected in both the clinical specimen and virus isolate

ce

(passage C1). The clinical specimen contained both H275Y (23%) and E119G. Plaque purification of
the original clinical sample in MDCK cells identified a H275Y-E119G double NA variant. When tested

Ac

by NI assay (Table 2), the virus carrying H275Y-E119G exhibited highly reduced inhibition by
oseltamivir (~2500-fold), zanamivir (~1500-fold), peramivir (>10,000-fold) and laninamivir (~600fold), compared to the wildtype reference virus, A/California/12/2012 (H1N1)pdm09. Peculiarly,
plaque-purification of the virus isolate (passage C1) yielded viruses containing only E119G (in 39 (46%)
of the 84 clones that were picked), and none with H275Y, suggesting that the virus carrying E119G had
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resistance to oseltamivir and peramivir. No amino acid changes were detected at residue I223, N295, or

7

growth advantage over the one with the dual substitution when propagated in MDCK cells in the
absence of NAIs. The phenotypic effect of the H275Y-E119D double variant (day -32 sample) on drug
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ipt

susceptibility was not determined due to unsuccessful attempts to recover the virus in cell culture.
Additional clinical specimens (n=19) collected from the patient from day -64 to day +45, relative
to transplantation, were tested by pyrosequencing at residues E119 and H275 (Table 1). The H275Y

substitution alone, in proportions of 95-100%, was detected in the first four samples collected between

us

day -64 and day -46; zanamivir treatment commenced on day -57. Five samples collected between day 39 and day -10 (the initial sample), had changes at residue E119, in addition to H275Y. Of note, the

an

those collected on day -39, -32, and -18 had 100% H275Y. A mix of E119G and E119D variants
(E119G/D) in addition to H275Y (100%) was detected in the sample from day -9, while that collected

M

on day -3 had only E119G/D, and those collected on day +3 and day +17, respectively, had E119G/D
with 34-37% H275Y. Two samples collected day +24 and day +34, respectively had E119G alone. The

DISCUSSION

pt
ed

viral RNA titers varied and did not directly reflect the detection of E119D/G (Table 1).

We report the emergence of an influenza A(H1N1)pdm09 virus infecting an

ce

immunocompromised infant after oseltamivir and zanamivir treatment, that carried the E119G
substitution in the NA. This change confers highly reduced inhibition to zanamivir, peramivir and

Ac

laninamivir. Moreover, a dual variant containing H275Y-E119G was detected and was highly resistant
to these three NAIs, in addition to oseltamivir. The presence of E119G potentiated the effects of H275Y

substitution, increasing IC50 values against oseltamivir by 2.5-fold, compared to the H275Y reference
virus A/Texas/32/2012 (H1N1)pdm09.To our knowledge, neither E119G nor the above combination of

substitutions, have previously been reported in A(H1N1)pdm09 viruses.
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samples collected on day -25 and day -10 contained only 16% and 23% H275Y, respectively, while
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No established laboratory test criteria exist for defining clinically relevant resistance to NAIs, but
highly reduced inhibition in the neuraminidase inhibition (NI) assay likely correlates with failure to
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control virus replication. Four NA substitutions, H275Y, I223R, D199N, and N295S, are recommended
by the WHO-AVWG for monitoring influenza antiviral drug susceptibility in viruses carrying the N1
NA; H275Y and I223R have been described most frequently. The pyrosequencing assay targeting

residue E119 will increase the scope of detecting neuraminidase (NA) markers of drug resistance in

us

A(H1N1)pdm09 viruses. There are no previous reports regarding the emergence of E119G or E119D in
influenza A(H1N1)pdm09 viruses in patients following zanamivir treatment. The E119G mutation has

an

presence of zanamivir and is associated with zanamivir-resistance (10,11). Recombinant
A(H1N1)pdm09 viruses with E119G mutation exhibited highly reduced inhibition by zanamivir and

M

peramivir, but were normally inhibited by oseltamivir (12), while those with E119D had zanamivir and
peramivir profiles similar to the E119G variant, but also exhibited reduced inhibition by oseltamivir.
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Finally, these substitutions have been reported infrequently from viruses infecting patients. The
substitutions E119K and E119D were identified by next-generation sequencing (NGS) in
A(H1N1)pdm09 viruses collected from patients hospitalized with influenza and treated with IV
zanamivir (13); only E119D was present in proportions detectable by Sanger sequencing. The E119G
mutation was detected during virological surveillance in 2011-12, in an influenza A(H1N1)pdm09 virus

ce

isolate from Chile, A/Iquique/44427/2012 that exhibited highly reduced inhibition by zanamivir (743fold) and laninamivir (113-fold), reduced inhibition by peramivir (85-fold), but normal inhibition by

Ac

oseltamivir (3-fold); treatment history was not available (L. Gubareva, personal communication).
The mechanisms by which mutations at residue 119 of A(H1N1)pdm09 viruses affect NAI

susceptibility remain unclear. The molecular structure of zanamivir, peramivir and laninamivir includes

a guanidine group (14), which interacts with the conserved E119 residue without undergoing a side
chain conformational change. Mutations at residue E119, such as E119D (12) that involves replacement
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been reported in N2 (e.g. A(H3N2)) (10), and A(H5N1) viruses (11) following serial passages in the
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of glutamic acid with aspartic acid, with a shorter side chain, may cause an unfavorable interaction with
NAIs and their natural substrate sialic acid. This may confer reduced sensitivity to the drugs.
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Furthermore, viruses carrying substitutions at residue 119 may have poor replication kinetics (15),
suggesting low potential for transmission. Studies demonstrate that E119G is associated with a

significant reduction of total NA activity (15), which alters NA enzymatic properties to levels that would
significantly compromise viral viability and transmissibility in ferrets. A recombinant A(H1N1)pdm09

us

virus with E119D showed impaired viral replicative fitness, but retained its growth properties and

pathogenicity in mice (12). Such findings may explain the low frequency of mutations at residue E119

an

Although uncommon, substitutions at residue E119 (e.g. E119G and E119D), can confer a
multidrug resistance phenotype in influenza A(H1N1)pdm09 viruses and may represent a problem for

M

immunocompromised patients on prolonged zanamivir treatment; further investigations of virus
virulence and transmission are warranted. In this infant, additional experimental therapies, such as

pt
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convalescent plasma, DAS181, or T705, were not tried due to signs of engraftment, a stable respiratory
status, and lack of product safety and efficacy data for infants. This report highlights the importance of
continuous surveillance and characterization of potential NAI multidrug-resistant influenza variants as

ce

well as the continued development of alternative therapeutic options for influenza.
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Table 1. Characterization of A(H1N1)pdm09 clinical specimens collected from an
immunocompromised patient treated with oseltamivir and zanamivir
Day
Relative to
CBTb

Clinical Influenza
Detection
Type (Subtype)

NAI Treatment

-121

Ac(H1N1)pdm09

Oseltamivir x 5 days

NP

-72

Ac(H1N1)pdm09

Oseltamivir x 5 days

NP

-64

A

Oseltamivir restarted

NW

5.23 x106

H275Y (100)

E119

-60

A

Oseltamivir

NW

2.24 x106

H275Y (95)

E119

H275Y (100)

E119

Negative

-51
-49

A

-46

Zanamivir IV

NP

Zanamivir IV

NP

0.21 x106

Zanamivir IV

NP

x106

Zanamivir IV

Swab

0.31

A

Zanamivir IV

NP

-32

Negative

Zanamivir IV

NP

-32

A

Zanamivir IV

NP

Zanamivir IV

Swab

-21

A

Zanamivir IV

-18

A

Zanamivir IV

-10d, e

A

Zanamivir IV
Zanamivir IV

e

H275Y (100)

E119G (40)/D (60)

--

E119G (71)/D (29)

0.96 x106

H275Y (34)

E119G (39)/D (61)

43.4 x106

H275Y (37)

E119G (74)/D (26)

H275Y (7)

E119G (100)

BAL

--

E119G (100)

ETT

--

--

--

--

--

--

NP
NP

e

+17 e

A

Zanamivir stopped

NW, NP e

+39
+45
+59

27.0

CSF

0

x106

x106

BAL

NP
ETT

Negative

ETT

Negative

ETT

Ac

+66

0.015

NP

BAL

ce

+39

pt
ed

NP

+34

E119G (100)

E119G (100) c

Zanamivir IV

A

H275Y(16)

E119G (100)

A

+32

E119D (100)

H275Y (23) c

+12

+31

H275Y (100)

H275Y (100)

NP

+28

E119G (100)

0.022 x106

Zanamivir IV

+27,
Engraftment

H275Y (ND)

NP d, e

A

A

E119

66.2 x106

+3

+24

H275Y (100)

NP

Zanamivir IV

0, CBT

119

BAL

M

-9

0.28 x106

an

-25

275 a

0

0

Abbreviations: CBT: cord blood transplantation; NW: nasal wash; NP: nasopharyngeal swab; CSF: celebrospinal fluid; ETT:
endotracheal tube aspirate;
“--" Pyrosequencing assay failed at respective residue.
a
Proportion of NA variants versus wildtype (in parenthesis) determined using single nucleotide polymorphism (SNP)
pyrosequencing analysis.
b
Only dates with data or a significant event are included in the table; other days were left off the Table.
c
The Respiratory Virus Panel assay: xTAGTM (Luminex Diagnostics) detected Type A, non H3N2 and non-seasonal H1N1.
It was assumed to be A(H1N1)pdm09.
d
Initial sample received at CDC.
e
Two separate specimens were tested for virus RNA load and NA substitutions.
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Changes at NA Residue
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Zanamivir IV started

-53

-3

Quantitative
PCR (copies/ml)

us

-57

Specimen
Source

14

Table 2. NAI susceptibility of influenza A(H1N1)pdm09 virus isolates assessed in the fluorescent NI assay
Mean IC50 ± SDb, nM (Fold change)c

Virus

Passage

275

119

Zanamivir

A/District of Columbia/02/2014

C1d

H275Y (5)

E119G (100)

235.05±27.17 (1306)

1.19±0.05 (7)

A/District of Columbia/02/2014, Clone 1

C2e

H275Y (100)

E119G (100)

278.34±69.91 (1546)

422.10±93.93 (2483)

A/California/12/2012, oseltamivir-susceptible

H275

-

0.18±0.02 (1)

0.17±0.01 (1)

A/Texas/32/2012, oseltamivir-resistant

H275Y

-

0.23±0.03 (1)

176.26±22.4 (1036)

a

sc

M
an
u

Reference viruses

Oseltamivir
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t

NA changes
(Frequency of variants, %)a

Peramivir

Laninamivir

8.33±0.39 (167)

49.01±5.89 (327)

4671.66±191.02 (93433)

90.78±6.91 (605)

0.05±00 (1)

0.15±0.02 (1)

15.66±2.05 (313)

0.35±0.03 (2)

Proportion of NA variants versus wildtype, determined using SNP pyrosequencing analysis.
Based on at least three independent experiments.
c
Fold increase (in bold) based on comparison to the respective IC50 values of the reference virus, A/California/12/2012.
d
C1 - Original clinical specimen passaged once in Madin Darby Canine Kidney (MDCK) cells at the CDC laboratory.
e
C2 - Original clinical specimen inoculated and plaque-purified in MDCK cells, then passaged once more in MDCK cells at the CDC laboratory.
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